Abstract. Pharmacogenomics is the study of the association between inter-individual genetic differences and drug responses. Researches in pharmacogenomics have been performed in compliance with the use of several genotyping technologies. In this study, a total of 392 single-nucleotide polymorphisms (SNPs) located in 141 pharmacogenes, including 21 phase I, 13 phase II, 18 transporter and 5 modifier genes, were selected and genotyped in 150 subjects using the GoldenGate assay or the SNaPshot technique. These variants were in Hardy-Weinberg equilibrium (HWE) (P>0.05), except for 22 SNPs. Genotyping of the 392 SNPs revealed that the minor allele frequencies of 47 SNPs were <0.05, 105 SNPs were monomorphic and 22 variants were not in HWE. Also, based on previous studies, we predicted the association between the polymorphisms of certain pharmacogenes, such as cytochrome P450 2D6, cytochrome P450 2C9, vitamin K epoxide reductase complex, subunit 1, cytochrome P450 2C19, human leukocyte antigen, class I, B and thiopurine S-methyltransferase, and drug efficacy. In conclusion, our study demonstrated the allele distribution of SNPs in 141 pharmacogenes as determined by high-throughput screening. Our results may be helpful in developing personalized medicines by using pharmacogene polymorphisms.
Introduction
Inter-individual variation in drug response among patients is a major obstacle in medicine application, due to the different response of each patient to the same medication (1) . Several cases of adverse drug reactions occurring in certain patients, such as renal/hepatic disorders, congestive heart failure and anemia, were previously reported (1, 2) . The variations in drug responses may result from disease determinants, genetics, environmental factors and idiosyncratic response, which collectively affect drug metabolism (3) . The knowledge of variations in efficacy and toxicity caused by the same doses of medications may enhance the effectiveness of drug therapy (3) .
The initial human genome sequencing identified ~1.42 million single-nucleotide polymorphisms (SNPs), including >60,000 SNPs in the exonic region of genes (4) . Some of these SNPs have been suggested to be associated with considerable changes in drug disposition and metabolism or the effects of medication (5-7), whereas others are used for the diagnosis of clinical response (8) . The interaction of several gene products is known to affect the pharmacokinetics and pharmacodynamics of medications. For example, inherited variations in drug targets, drug disposition and polygenic factors of drug effects are determinants of the majority of drug effects and have become increasingly important in pharmacogenomics (9) .
Pharmacogenomics is the study of how genetic differences among individuals affect the variability in their response to medications (6, 10) . Pharmacogenomic research includes clinical and basic science regarding genetic variation and drug response. The field of pharmacogenomics has attracted significant attention along with the completion of the Human Genome Project (11) . Consequently, there has been an increase in the number of pharmacogenomic studies published (11) . Furthermore, the continuous development of genotyping technologies may allow pharmacogenomic applications to move into the mainstream of medicine and pharmacy practice (12, 13) .
Over the last few years, the available technologies for genomic analyses have increased significantly (14) . For example, the TaqMan and the SNPlex assays from Applied Biosystems (Foster City, CA, USA), the GeneChip assay from Affymetrix (Santa Clara, CA, USA) and the Infinium and GoldenGate assays developed by Illumina (San Diego, CA, USA) are the most frequently used techniques in genome research (15) . In addition, the SNaPshot technique has been tested on a small scale of multiplex for analysis of gene polymorphisms (16) . In this study, we used the GoldenGate assay and the SNaPshot technique for genotyping to investigate the 3 genes were all located in the X chromosome, although located far away from each other (G6PD at Xq28, ATP7A at Xq21.1 and HTR2C at Xq24). The classifications and SNP numbers of each pharmacogene investigated in this study are listed in Table IV . Among these, cytochrome P450 2D6 (CYP2D6), cytochrome P450 2C19 (CYP2C19), thiopurine S-methyltransferase (TPMT), cytochrome P450 2C9 (CYP2C9), vitamin K epoxide reductase complex, subunit 1 (VKORC1) and human leukocyte antigen, class I, B (HLA-B) are of great significance, due to their association with well-known drugs. Therefore, we investigated the respective genes and their effects on enzyme activity or associated drugs below.
First . CYP2D6 is one of the most important pharmacogenes involved in the metabolism of foreign substances in the body. Overall, the genotypes associated with decreased activity or a non-functional enzyme were ~20% of all the investigated genotypes (Table V) . Specifically, screening of polymorphisms such as rs3892097, rs1065852, rs16947 and rs1135840 may be useful for detecting the enzyme activity level of CYP2D6. CYP2C19 is clinically important for the metabolism of drugs including clopidogrel (20) , which is an inhibitor of adenosine diphosphate-induced platelet aggregation (21) (22) (23) (Table V) . In general, over half of the subjects were found to have genotypes that reduced the efficacy of clopidogrel, while 11.5% of the subjects carried genotypes which enhanced the efficacy of clopidogrel. This information may be used to adjust the dose of clopidogrel depending on the patient genotypes of the investigated polymorphisms.
TPMT encodes an enzyme involved in the detoxification of azathioprine, mercaptopurine and thioguanine, which are immunosuppressive drugs used in organ transplantation (24) (25) (26) (27) (Table V) . The results suggested that the majority of Korean subjects have TPMT genotypes, which render them more prone to the toxicity of the aforementioned drugs. The dihydropyrimidine dehydrogenase gene (DPYD) encodes an enzyme catabolizing 5-fluorouracil (5-FU), which is commonly used for the treatment of solid carcinomas (28, 29) . A decrease in enzyme activity involved in 5-FU catabolism due to the mutational variants in DPYD may lead to an increase in the half-life of 5-FU and an increased risk of dose-dependent toxicity (28, 30, 31) . In our study, all the Korean subjects were found to carry the DPYD genotypes associated with normal enzyme activity ( Table V) . A polymorphism of interleukin 28B (IL28B), rs8099917 has been reported to be associated with the virologic response to peginterferon-α (PEG-IFNα) and ribavirin (RBV) combination therapy in hepatitis C virus-infected patients (32) (33) (34) , whereas the GT and GG genotypes of rs8099917 have been suggested to be less responsive to treatment compared to TT (32) . In this study, subjects carrying the TT genotype were the most common (86.7%), whereas the GT and GG genotypes were significantly less frequent (12.7 and 0.7%, respectively) in the Korean population (Table V) . These results may be used to identify patients with reduced responsiveness to PEG-IFNα̸RBV combined therapy and adjust the amount accordingly.
Warfarin is an anticoagulant used for the prevention of thromboembolic events and stroke (35 3), which was also observed in European and African-American populations (42) . As regards rs8050894 in VKORC1, an overall higher warfarin dose requirement in CG (heterozygote) or CC (minor homozygote) compared to that in GG (major homozygote) was observed. However, in European and African-American populations, GG exhibited a higher warfarin dose requirement compared to the CG or CC genotype (42) . Further investigations may be required to verify the different genetic effect on warfarin response in various ethnic groups.
HLA-B encodes for a protein which is an important part of the human immune system and its polymorphisms have been associated with various drug reactions (43) (44) (45) . Carbamazepine, which is often used for treatment of chronic pain, bipolar disorder, seizure disorder and trigeminal neuralgia, is one of the most common causes of drug hypersensitivity reactions (46 
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